A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

Sponsor
Eli Lilly and Company
Study ID
NCT06916091
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Eloralintide — DRUG
    Administered subcutaneously (SC)
  • Placebo — DRUG
    Administered SC

Study Details

The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much Eloralintide gets into the bloodstream and how long it takes the body to eliminate it. The study will last approximately 10 weeks excluding a screening period.

Key Dates

Start date
Apr 21, 2025
Status verified
Nov 2025
Primary completion
Sep 9, 2025
Completion
Sep 9, 2025

Study Design

Enrollment
30 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Eloralintide
    Eloralintide administered subcutaneously (SC)
  • Placebo Comparator: Placebo
    Placebo administered SC

Primary Outcome Measure

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline to Study Completion (Up to 10 Weeks) ]

Related Studies